COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the...

Full description

Bibliographic Details
Main Authors:	Monika Gawałko, Agnieszka Kapłon-Cieślicka, Mathias Hohl, Dobromir Dobrev, Dominik Linz
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	International Journal of Cardiology: Heart & Vasculature
Subjects:	Anticoagulation Arrhythmia Inflammasome Remote monitoring Thromboembolic risk
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352906720303298

Similar Items

Clinical Profile and One Year Outcome of Atrial Fibrillation- A Prospective Cohort Study
by: Praveen Satheesan, et al.
Published: (2020-09-01)

Risk of left atrial appendage thrombus in older patients with atrial fibrillation
by: Monika Gawałko, et al.
Published: (2021-03-01)

Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation
by: Tomas Forslund, et al.
Published: (2021-08-01)

Kidney Function and the Use of Vitamin K Antagonists or Direct Oral Anticoagulants in Atrial Fibrillation
by: Gencheva Dolina
Published: (2023-09-01)

Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?
by: Monika Gawałko, et al.
Published: (2021-06-01)

Anticoagulation for Atrial Fibrillation after Resolution of Dengue Haemorrhagic Fever
by: Henrique Horta Veloso
Published: (2016-03-01)

Secondary prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation – clinical practice in relation to guidelines
by: Bernadetta Bielecka, et al.
Published: (2023-06-01)

Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial
by: Paweł Balsam, et al.
Published: (2021-04-01)

The gut microbial-derived metabolite trimethylamine N-oxide: A missing link between lifestyle-components and atrial fibrillation?
by: Monika Gawałko, et al.
Published: (2020-08-01)

Impact of an Emergency Department Observation Unit Management Algorithm for Atrial Fibrillation
by: Shawna D. Bellew, et al.
Published: (2016-02-01)

Atrial fibrillation: non cardiologist physicians approach
by: Forero-Gómez, Julián Eduardo, et al.
Published: (2017-10-01)

Sleep apnea and atrial fibrillation: Update 2020
by: Dominik Linz, et al.
Published: (2020-12-01)

Fat chance for POAF? Pericardial adipose tissue and the arrhythmogenic substrate for postoperative atrial fibrillation
by: Monika Gawałko, et al.
Published: (2022-04-01)

Surgery-related cardiac stress: A susceptibility test of late atrial fibrillation recurrence?
by: Monika Gawałko, et al.
Published: (2021-02-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)

Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
by: Liane O. Dallalzadeh, et al.
Published: (2016-07-01)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
by: Iwona Gorczyca, et al.
Published: (2020-11-01)

Drug Therapy in Atrial Fibrillation Management: Where Do We Stand in 2010?
by: Gholamreza Davoodi, et al.
Published: (2010-10-01)

Drug Therapy in Atrial Fibrillation Management: Where Do We Stand in 2010?
by: Mehdi Montazeri, et al.
Published: (2010-11-01)

Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis
by: Eng-Loon Tng, et al.
Published: (2022-05-01)

Direct oral anticoagulation and severe obesity – One size fits all?
by: Anke C. Fender, et al.
Published: (2021-12-01)

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

How to level the risk of bleeding while taking anticoagulant therapy in patients with atrial fibrillation?
by: Svetlana A. Berns, et al.
Published: (2022-01-01)

Why Did All Patients with Atrial Fibrillation and High Risk of Stroke Not Receive Oral Anticoagulants? Results of the Polish Atrial Fibrillation (POL-AF) Registry
by: Anna Szpotowicz, et al.
Published: (2021-10-01)

Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry
by: Monika Gawałko, et al.
Published: (2021-03-01)

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis
by: Ciuculete Denisa-Corina, et al.
Published: (2021-09-01)

Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016-09-01)

Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors
by: Vineet Kumar, et al.
Published: (2024-02-01)

Risk factors for left atrial thrombus in younger patients (aged < 65 years) with atrial fibrillation or atrial flutter: Data from the multicenter left atrial thrombus on transesophageal echocardiography (LATTEE) registry
by: Beata Uziȩbło-Życzkowska, et al.
Published: (2022-10-01)

Does weight matter in cryoballoon ablation?
by: Monika Gawałko, et al.
Published: (2023-08-01)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
by: Alexandros Briasoulis, et al.
Published: (2018-04-01)

Current clinical practice guidelines in atrial fibrillation: a review
by: osé Kelvin Galvez-Olortegui, et al.
Published: (2016-03-01)

Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery
by: Bo Eun Park, et al.
Published: (2020-10-01)

Prevalence, predictors and management of left atrial appendage thrombogenic milieu in atrial fibrillation with low thromboembolic risk
by: Yu Qiao, et al.
Published: (2023-03-01)

Surgical Ablation of Atrial Fibrillation in Patients Undergoing Bioprosthetic Valve Replacement
by: WonKyung Pyo, et al.
Published: (2019-04-01)

Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system
by: Sushmita Malik, et al.
Published: (2023-11-01)

Reliability and safety of long-term dabigatran use in patients with atrial fibrillation
by: E. V. Serdechnaya, et al.
Published: (2013-04-01)

Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate
by: Stanley Nattel, MD
Published: (2016-08-01)

Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease
by: Kuo-Hua Lee, et al.
Published: (2021-10-01)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023-02-01)